Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1752)	2/26/2003 5:54:05 PM
From: Icebrg	Read Replies (2) \| Respond to of 2243

Wilder >> I'm sure you noticed the patent on S is a big issue. An oral agent expiring '09/'10, with NDA not expected until '06? That's not much time to see the off-label adoption they hope for. What patent extension strategy do you think they have in mind?>> I was aware that there should be a patent issue. Considering that the drug has been around for quite some time. But I didn't have the details. I have no idea what they will do with the patent issues. On the other had - considering the expertise that is on hand both at Spectrum and at GPC, I just assumed that this is something that they have thought about. This should actually be more of a threat to GPC then to SPPI. The latter is so small that any income should have a good impact on their valuation. Orphan drug status is the protection that first comes to my mind. But the prostate cancer indication will not support orphan status. >>Plus, it's partnered to GPC, GPC will need to partner once again. So.....>> That's OK as long as some money flows back to SPPI. Clearly GPC wouldn't be able to do anything with the drug in the US. Perhaps BMY would be happy to in-license the drug. :-). SPPI's basic strategy at the moment is one of survival. They have to be able to keep some funds coming their way. If Satraplatin can do that until 2009/2010 they have made a very good deal IMHO. You have to keep in mind that their market cap. is only 3 mUSD. Any little indication of a steady future income stream should easily move them to say 10 mUSD for an easy three-bagger. On the other hand their financial situation is still very fragile. Although I think that they have escaped the worst. It's an interesting company to follow, because they are so different from almost anything else. Erik